阿奇霉素治疗细菌性性传播感染的药代动力学考量:综述
细菌性性传播感染发病率持续上升,淋球菌和生殖支原体耐药及生殖器外部位感染(直肠衣原体、口咽淋病)使治疗面临挑战。本文综述阿奇霉素等抗菌药物的药代动力学,分析药物、宿主和病原体因素对疗效的影响,并提出延长或高剂量给药的剂量方案建议,同时指出口咽淋病及头孢曲松药代动力学数据有限。
要点
- 阿奇霉素药代动力学受组织分布、蛋白结合、半衰期及感染部位pH和炎症影响。
- 淋球菌和生殖支原体耐药及生殖器外部位感染是当前治疗的主要挑战。
- 口咽淋球菌感染的头孢曲松药代动力学及与阿奇霉素联用数据非常有限。
核心结论
- 需优化现有抗菌药物方案以应对耐药和生殖器外部位感染,但药代动力学指导治疗方案的稳健数据缺乏。
- 阿奇霉素是治疗衣原体、淋病和生殖支原体感染的主要药物,其药代动力学研究较充分。
- 未来不同解剖部位的感染可能需要替代治疗策略。
研究设计与样本
- 综述,总结已发表的用于治疗性传播感染的抗菌药物药代动力学数据。
主要发现
- 药物因素(组织分布、蛋白结合、半衰期)、宿主因素(pH、炎症、感染部位、药物副作用、性行为)和病原体因素(病原体载量、抗菌药物耐药)均可影响治疗结局。
- 口咽淋球菌感染的头孢曲松药代动力学及其与阿奇霉素联用的数据非常有限。
临床怎么用
- 使用延长或更高剂量阿奇霉素时,应参考本文提出的剂量方案建议以平衡疗效与副作用。
- 临床需考虑感染解剖部位对药代动力学和疗效的影响,尤其是直肠衣原体和口咽淋病。
局限性
- 已发表的药代动力学研究存在局限性,口咽淋球菌感染相关数据非常有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rates of bacterial sexually transmitted infections (STIs) continue to rise, demanding treatments to be highly effective. However, curing infections faces significant challenges due to antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium and especially treating STIs at extragenital sites, particularly rectal chlamydia and oropharyngeal gonorrhoea. As no new antimicrobials are entering the market, clinicians must optimize the currently available treatments, but robust data are lacking on how the properties or pharmacokinetics of antimicrobials can be used to inform STI treatment regimens to improve treatment outcomes. This paper provides a detailed overview of the published pharmacokinetics of antimicrobials used to treat STIs and how factors related to the drug (tissue distribution, protein binding and t½), human (pH, inflammation, site of infection, drug side effects and sexual practices) and organism (organism load and antimicrobial resistance) can affect treatment outcomes. As azithromycin is commonly used to treat chlamydia, gonorrhoea and M. genitalium infections, and its pharmacokinetics are well studied, it is the main focus of this review. Suggestions are also provided on possible dosing regimens when using extended and/or higher doses of azithromycin, which appropriately balance efficacy and side effects. The paper also emphasizes the limitations of currently published pharmacokinetic studies including oropharyngeal gonococcal infections, where very limited data exist around ceftriaxone pharmacokinetics and its use in combination with azithromycin. In future, the different anatomical sites of infections may require alternative therapeutic approaches.
引用
- Kong FYS, Horner P, Unemo M, et al. Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. J Antimicrob Chemother. 2019. PMID: 30649333. doi:10.1093/jac/dky548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。